Affordable Access

Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer.

Authors
Type
Published Article
Journal
British journal of cancer
Publication Date
Volume
95
Issue
9
Pages
1142–1144
Identifiers
PMID: 17031394
Source
Medline
License
Unknown

Abstract

Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median follow-up of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0-4.9).

Statistics

Seen <100 times